Company profile: Courier Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology solutions, including a protein therapeutics platform aimed at making cancer immunotherapy safer and more efficacious, with potential in autoimmune and inflammatory diseases; AI-driven drug discovery offerings such as the Opal Computational Platform, Target Discovery, and Logica; and development of investigational therapies like OPL-0401 for diabetic retinopathy.
Products and services
- Opal Computational Platform: An AI-driven drug development engine leveraging human data to identify and validate novel targets, accelerating discovery and development of small-molecule therapies
- Logica: An integrated drug discovery product, developed with Charles River, engineered to rapidly deliver optimized preclinical assets using AI
- Target Discovery: A machine-learning process using human data to identify disease-associated targets and biomarkers, bypassing traditional models like cell or animal studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Courier Therapeutics
Sutro Biopharma
HQ: United States
Website
- Description: Provider of protein therapeutics leveraging OCFS and XpressCF cell-free protein synthesis, with an ADC pipeline: luveltamab tazevibulin (luvelta) targeting folate receptor alpha in clinical studies for platinum-resistant ovarian cancer; STRO-003 (ROR1-targeting) under a global licensing agreement with potential milestones and royalties; STRO-004 (tissue factor-targeting) planned for 2025 IND; plus sustainability efforts and a summer internship program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sutro Biopharma company profile →
Sellas Life Sciences
HQ: Bermuda
Website
- Description: Provider of late-stage cancer immunotherapies, developing Galinpepimut-S (GPS), a WT1-targeting synthetic heteroclitic epitope immunotherapeutic for various cancers to prevent relapses and potentially improve survival, and SLS009, a highly selective small molecule CDK9 inhibitor for development and commercialization worldwide outside the Greater China Region.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sellas Life Sciences company profile →
Oncorus
HQ: United States
Website
- Description: Provider of immuno-oncology solutions developing oncolytic viruses to fight cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncorus company profile →
Onyvax
HQ: United Kingdom
Website
- Description: Provider of cancer therapies that harness the immune system’s selective power to seek out and destroy tumor cells, specifically targeting cancer cells to improve effectiveness while minimizing side effects compared to conventional treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onyvax company profile →
Simcha Therapeutics
HQ: United States
Website
- Description: Provider of engineered cytokine immunotherapies for cancer, including ST-067, an engineered IL-18 variant designed to overcome the IL-18BP decoy receptor, in Phase 1 trials for solid tumors; ST-067 plus Keytruda® in Phase 1; preclinical ST-067 combination therapies; and undisclosed cytokine therapeutic programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Simcha Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Courier Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Courier Therapeutics
2.2 - Growth funds investing in similar companies to Courier Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Courier Therapeutics
4.2 - Public trading comparable groups for Courier Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →